Severe Thrombocytopenia Associated with Acute Hepatitis E Virus Infection

Colson, Philippe; Payraudeau, E.; Léonnet, Caroline; Montigny, Stéphanie De; Villeneuve, Laurent; Motte, Anne; Tamalet, Catherine

doi:10.1128/jcm.02295-07

Cited by 49 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…individuals, including organ transplant recipients [5], patients receiving chemotherapy [6], and HIV-infected individuals [7]. Additionally, nonhepatic complications associated with HEV infection, such as neurologic disorders and pancreatitis, have been reported [8][9][10][11].…”

Section: Introductionmentioning

confidence: 98%

Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission

Zhang

Zeng

Liu

et al. 2015

Vaccine

View full text Add to dashboard Cite

Hepatitis E virus (HEV) infection has become a significant global public health concern as increasing cases of acute and chronic hepatitis E are reported. HEV of animal origin was proved to be a possible source of human infection and a previous study showed that the recent licensed HEV 239 vaccine can serve as a candidate vaccine to manage animal sources of HEV infection. However, previous immunization strategy for rabbits was the same as that for human, which is too costly to conduct large-scale animal vaccination. In an effort to reduce the costs, three vaccination schemes were assessed in the present study. Forty specific pathogen-free (SPF) rabbits were divided randomly into five groups with eight animals for each and inoculated intramuscularly with different doses of HEV 239 and placebo, respectively. All animals were challenged intravenously with swine HEV-4 and rabbit HEV of different titers 7 weeks after the initial immunization and then fecal virus excretion was monitored for 10 weeks. The results indicated that immunizing rabbits with two 10μg doses of the vaccine is superior to vaccination with two 20μg doses or a single 30μg dose, which can protect rabbits against homologous and heterologous HEV infection. These findings could enable implementation of large-scale animal vaccination to prevent rabbit HEV infection and zoonotic transmission.

show abstract

Section: Introductionmentioning

confidence: 98%

Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission

Zhang

Zeng

Liu

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…6 The mechanism of thrombocytopenia in the context of viral infection is thought to be immune mediated.…”

mentioning

confidence: 99%

Severe thrombocytopenia associated with acute autochthonous hepatitis E

Fourquet¹,

Mansuy²,

Bureau³

et al. 2010

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Extrahepatic manifestations such as hematological manifestations (8)(9)(10), acute pancreatitis (11), kidney injuries (12), or neurological manifestations can also occur (13)(14)(15).…”

mentioning

confidence: 99%

Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy

Lhomme

Kamar

Nicot³

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

m Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients (P ‫؍‬ 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment.

show abstract

Severe Thrombocytopenia Associated with Acute Hepatitis E Virus Infection

Cited by 49 publications

References 12 publications

Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission

Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission

Severe thrombocytopenia associated with acute autochthonous hepatitis E

Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy

Contact Info

Product

Resources

About